drugset / Trial / NCT07079228

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

NCT07079228

Phase 3 Recruiting 602 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this study is to evaluate the efficacy of QLS31905 in combination with chemotherapy (nab-paclitaxel plus gemcitabine \[AG\]) versus placebo in combination with chemotherapy (AG) in the treatment of CLDN18.2-positive advanced pancreatic cancer in adult participants.

Timeline

Start
2025-09-08
Primary completion
2028-12
Completion
2030-09

Drugs

EvaluationDrugModalityDoseRoute
Subject QLS31905 Unknown Intravenous
Comparator Gemcitabine Small molecule Intravenous
Comparator Paclitaxel Small molecule Intravenous